Drugs for HER-2-positive Breast Cancer

Nonfiction, Health & Well Being, Medical, Medical Science, Pharmacology, Specialties, Oncology
Cover of the book Drugs for HER-2-positive Breast Cancer by , Springer Basel
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783034600941
Publisher: Springer Basel Publication: January 6, 2011
Imprint: Springer Language: English
Author:
ISBN: 9783034600941
Publisher: Springer Basel
Publication: January 6, 2011
Imprint: Springer
Language: English

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

More books from Springer Basel

Cover of the book Developments of Harmonic Maps, Wave Maps and Yang-Mills Fields into Biharmonic Maps, Biwave Maps and Bi-Yang-Mills Fields by
Cover of the book Control and Optimization with PDE Constraints by
Cover of the book Proofs of the Cantor-Bernstein Theorem by
Cover of the book IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity by
Cover of the book Berichte zur Lebensmittelsicherheit 2011 by
Cover of the book Influenza Virus Sialidase - A Drug Discovery Target by
Cover of the book Signposts to Chiral Drugs by
Cover of the book For Better or For Worse? Collaborative Couples in the Sciences by
Cover of the book T Lymphocytes as Tools in Diagnostics and Immunotoxicology by
Cover of the book Fractal Symmetry of Protein Exterior by
Cover of the book Fractal Symmetry of Protein Interior by
Cover of the book And Yet It Is Heard by
Cover of the book Mathematicians in Bologna 1861–1960 by
Cover of the book Special Functions of Mathematical (Geo-)Physics by
Cover of the book Introduction to Quantitative Methods for Financial Markets by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy